Fabienne Langlois1,2, Dawn Shao Ting Lim1,3, Chris G Yedinak4,5, Isabelle Cetas4, Shirley McCartney4,5, Justin Cetas4,5, Aclan Dogan4,5, Maria Fleseriu6,7,8. 1. Department of Medicine, Oregon Health & Science University, Portland, OR, USA. 2. Department of Medicine Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Quebec, Canada. 3. Department of Endocrinology, Singapore General Hospital, Singapore, Singapore. 4. Department of Neurological Surgery, Oregon Health & Science University, Mail Code CH8N, 3303 SW Bond Avenue, Portland, OR, 97239, USA. 5. Northwest Pituitary Center, Oregon Health & Science University, Portland, OR, USA. 6. Department of Medicine, Oregon Health & Science University, Portland, OR, USA. fleseriu@ohsu.edu. 7. Department of Neurological Surgery, Oregon Health & Science University, Mail Code CH8N, 3303 SW Bond Avenue, Portland, OR, 97239, USA. fleseriu@ohsu.edu. 8. Northwest Pituitary Center, Oregon Health & Science University, Portland, OR, USA. fleseriu@ohsu.edu.
Abstract
PURPOSE: Silent corticotroph adenomas (SCAs) are clinically silent and non-secreting, but exhibit positive adrenocorticotropic hormone (ACTH) immunostaining. We characterized a single center cohort of SCA patients, compared the SCAs to silent gonadotroph adenomas (SGAs), identified predictors of recurrence, and reviewed and compared the cohort to previously published SCAs cases. METHODS: Retrospective review of SCA and SGA surgically resected patients over 10 years and 6 years, respectively. Definitions; SCA-no clinical or biochemical evidence of Cushing's syndrome and ACTH positive immunostaining, and SGA-steroidogenic factor (SF-1) positive immunostaining. A systematic literature search was undertaken using Pubmed and Scopus. RESULTS: Review revealed 814 pituitary surgeries, 39 (4.8%) were SCAs. Mean follow-up was 6.4 years (range 0.5-23.8 years). Pre-operative magnetic resonance imaging demonstrated sphenoid and/or cavernous sinus invasion in 44%, 33% were > 50% cystic, and 28% had high ACTH levels pre-operatively. Compared to SGAs (n = 70), SCAs were of similar size and invasiveness (2.5 vs. 2.9 cm, p = 0.2; 44 vs. 41%, p = 0.8, respectively), but recurrence rate was higher (36 vs. 10%, p = 0.001) and more patients received radiation therapy (18 vs. 3%, p = 0.006). Less cystic tumors (0 vs. 50%, p < 0.001) and higher pre-operative ACTH levels (54 vs. 28 pg/ml, p = 0.04) were predictors of recurrence for SCAs. CONCLUSION: This review is unique; a strict definition of SCA was used, and single center SCAs were compared with SGAs and with SCAs literature reviewed cases. We show that SCAs are aggressive and identify predictors of recurrence. Accurate initial diagnosis, close imaging and biochemical follow up are warranted.
PURPOSE: Silent corticotroph adenomas (SCAs) are clinically silent and non-secreting, but exhibit positive adrenocorticotropic hormone (ACTH) immunostaining. We characterized a single center cohort of SCA patients, compared the SCAs to silent gonadotroph adenomas (SGAs), identified predictors of recurrence, and reviewed and compared the cohort to previously published SCAs cases. METHODS: Retrospective review of SCA and SGA surgically resected patients over 10 years and 6 years, respectively. Definitions; SCA-no clinical or biochemical evidence of Cushing's syndrome and ACTH positive immunostaining, and SGA-steroidogenic factor (SF-1) positive immunostaining. A systematic literature search was undertaken using Pubmed and Scopus. RESULTS: Review revealed 814 pituitary surgeries, 39 (4.8%) were SCAs. Mean follow-up was 6.4 years (range 0.5-23.8 years). Pre-operative magnetic resonance imaging demonstrated sphenoid and/or cavernous sinus invasion in 44%, 33% were > 50% cystic, and 28% had high ACTH levels pre-operatively. Compared to SGAs (n = 70), SCAs were of similar size and invasiveness (2.5 vs. 2.9 cm, p = 0.2; 44 vs. 41%, p = 0.8, respectively), but recurrence rate was higher (36 vs. 10%, p = 0.001) and more patients received radiation therapy (18 vs. 3%, p = 0.006). Less cystic tumors (0 vs. 50%, p < 0.001) and higher pre-operative ACTH levels (54 vs. 28 pg/ml, p = 0.04) were predictors of recurrence for SCAs. CONCLUSION: This review is unique; a strict definition of SCA was used, and single center SCAs were compared with SGAs and with SCAs literature reviewed cases. We show that SCAs are aggressive and identify predictors of recurrence. Accurate initial diagnosis, close imaging and biochemical follow up are warranted.
Authors: B W Scheithauer; A J Jaap; E Horvath; K Kovacs; R V Lloyd; F B Meyer; E R Laws; W F Young Journal: Neurosurgery Date: 2000-09 Impact factor: 4.654
Authors: Wolfgang Saeger; Dieter K Lüdecke; Michael Buchfelder; Rudolf Fahlbusch; Hans-Jürgen Quabbe; Stephan Petersenn Journal: Eur J Endocrinol Date: 2007-02 Impact factor: 6.664
Authors: V Popovic; D Micic; M Nesovic; T Howlett; I Doniach; A Kendereski; P Djordjevic; D Manojlovic; J Micic; M Besser Journal: Exp Clin Endocrinol Date: 1990-11
Authors: P D Delgado-López; J Pi-Barrio; M T Dueñas-Polo; M Pascual-Llorente; M C Gordón-Bolaños Journal: Clin Transl Oncol Date: 2018-04-05 Impact factor: 3.405
Authors: José Miguel Hinojosa-Amaya; César Ernesto Lam-Chung; Daniel Cuevas-Ramos Journal: Front Endocrinol (Lausanne) Date: 2021-04-26 Impact factor: 5.555
Authors: M E Torregrosa-Quesada; A García-Martínez; A Sánchez-Barbie; S Silva-Ortega; R Cámara; C Fajardo; C Lamas; I Aranda; A Pico Journal: J Endocrinol Invest Date: 2021-01-21 Impact factor: 4.256
Authors: Nicholas A Tritos; Pouneh K Fazeli; Ann McCormack; Susana M Mallea-Gil; Maria M Pineyro; Mirjam Christ-Crain; Stefano Frara; Artak Labadzhyan; Adriana G Ioachimescu; Ilan Shimon; Yutaka Takahashi; Mark Gurnell; Maria Fleseriu Journal: Pituitary Date: 2021-07-20 Impact factor: 4.107